PTPN11 and non-small cell lung carcinoma: Results from a phase 1 clinical trial using RMC-4630, a selective SHP2 inhibitor, show some early evidence of efficacy in NSCLC patients harbouring a KRASG12C mutation, with 71% (5/7) of patients showing disease control [63].